Diagnostic Value of 18F-labeled PSMA PET/CT for Regional Lymph Node Metastasis in Prostate Cancer: A Meta-analysis
10.3971/j.issn.1000-8578.2022.21.0752
- VernacularTitle:18F标记的PSMA PET/CT对前列腺癌区域淋巴结转移诊断价值的Meta分析
- Author:
Chunyuan ZENG
1
;
Yong CHENG
;
Hao XU
Author Information
1. Department of Nuclear Medicine, The First Affiliated Hospital of Ji'nan University, Guangzhou 510630, China
- Publication Type:Research Article
- Keywords:
18F;
PSMA;
PET/CT;
Prostate cancer;
Lymph node;
Meta-analysis
- From:
Cancer Research on Prevention and Treatment
2022;49(2):141-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the diagnostic value of 18F-labeled PSMA PET/CT for regional lymph node metastasis in prostate cancer. Methods We searched PubMed, Embase, Cochrane Library, Web of Science, CNKI, VIP and Wanfang database from January 1, 2000 to May 31, 2021 for the studies about the diagnosis of 18F-labeled PSMA PET/CT for regional lymph node metastasis and staging in prostate cancer. Two investigators screened literature, extracted relevant data and assessed the quality of the literature independently. The meta-analysis was performed using Meta-disc 1.4 and Stata 16.0 software. Results A total of 8 studies were finally included for the analysis, consisting of 754 prostate cancer patients and 2101 lymph nodes. The results of this meta-analysis showed pooled sensitivity, pooled specificity, pooled positive likelihood ratio, pooled negative likelihood ratio and diagnostic ratio were 0.82 (95%CI: 0.61-0.93), 0.98 (95%CI: 0.91-1.00), 45.7 (95%CI: 9.0-231.3), 0.18 (95%CI: 0.07-0.45) and 251 (95%CI: 34-1851), respectively. The area under the SROC curve was 0.97 (95%CI: 0.95-0.98). Conclusion 18F-labeled PSMA PET/CT has a high diagnostic value for regional lymph node metastasis in prostate cancer.
